ClinicalTrials.gg
CompletedNCT07324642Updated Jan 7, 2026

A Phase 1 MAD Study of KINE-101 in Healthy Volunteers

A Phase 1 interventional study of KINE-101 and Placebo in Healthy Volunteers, sponsored by Kine Sciences Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Kine Sciences Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, single-center, single-blind, placebo-controlled, dose-escalation Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of multiple intravenous (IV) infusions of KINE-101 in healthy adult volunteers.

The study includes three sequential cohorts with a total of 24 subjects (8 subjects per cohort; 6 assigned to KINE-101 and 2 to placebo). Subjects in the treatment groups receive KINE-101 once daily for 7 consecutive days at doses corresponding to their assigned cohort (Cohort 1: 120 mg, Cohort 2: 240 mg, Cohort 3: 360 mg). Subjects in the placebo group receive 0.9% saline under identical conditions. All subjects are admitted on Day -1, receive daily dosing from Day 1 through Day 7, and are discharged on Day 9 after completion of safety monitoring. Follow-up visits are conducted on Days 14, 21, 28, and 35. Dose escalation proceeds sequentially from the lowest-dose cohort (Cohort 1) to the highest-dose cohort (Cohort 3). Safety and tolerability data collected through Day 35 in each preceding cohort are reviewed before initiating dosing in the next higher-dose cohort.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Kine Sciences Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female adults aged 19 to 55 years
  • Body weight ≥ 50.0 kg and (BMI) between 18.5 and 30.0 kg/m²
  • Clinically healthy with no congenital or chronic diseases requiring treatment
  • Normal findings in physical examination, vital signs, 12-lead , and clinical laboratory tests at screening
  • Provided written and willing to comply with all study restrictions and procedures

Exclusion criteria

Exclusion Criteria:

  • History or presence of hepatic, renal, cardiovascular, respiratory, neurological, hematologic, endocrine, psychiatric, or malignant diseases
  • Abnormal findings ( > 450 ms for males or > 470 ms for females; PR > 200 ms; QRS > 120 ms)
  • Abnormal liver or renal function (, ALT, ALP, γ-GT, or total > 2× ; \< 60 mL/min/1.73 m²)
  • Positive drug abuse test or history of substance abuse
  • Abnormal vital signs at screening (SBP ≤ 90 or ≥ 150 mmHg; DBP ≤ 60 or ≥ 100 mmHg; pulse ≤ 40 or ≥ 100 bpm)
  • Vaccination with live or attenuated vaccines or systemic use within 3 months before dosing
  • Use of enzyme-inducing/inhibiting drugs, herbal medicines, or other products within 1-3 months before dosing
  • Donation or transfusion of blood within 3 months before dosing
  • Regular alcohol consumption > 21 units/week, or inability to abstain during the study
  • Current smokers (> 10 cigarettes/day) or inability to refrain from smoking during study participation
  • Intake of alcohol, grapefruit, quinine, Seville orange, or caffeine-containing products within 24-72 hours before dosing and during sampling periods
  • Engagement in strenuous exercise within 48 hours before dosing
  • Pregnant or breastfeeding women, or men and women not using reliable
  • Recent COVID-19 or influenza infection or vaccination within 2 weeks before dosing
  • Difficult venous access or positive alcohol breath test
  • Any other condition that, in the investigator's judgment, would make the subject unsuitable for participation in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    KINE-101

    Drug: KINE-101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • KINE-101 injection, 12.5 mg/mL, intravenous infusion once daily for 7 days under fasting conditions.

  • DrugPlacebo

    0.9% sodium chloride, intravenous infusion once daily for 7 days under fasting conditions.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Number and percentage of subjects experiencing any treatment-emergent adverse event (TEAE) following multiple intravenous administrations of KINE-101 or placebo. Safety assessments will also include concomitant medications, physical examinations, local injection site reactions, and vital signs.

    Time frame: From Day 1 to Day 35 (End of Study visit)

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) of KINE-101 following single and multiple doses.

    Time frame: From Day 1 (pre-dose) through Day 7 post-dose

  2. Area under the plasma concentration-time curve (AUC)

    Area under the plasma concentration-time curve (AUC) of KINE-101 following single and multiple doses.

    Time frame: From Day 1 (pre-dose) through Day 7 post-dose

  3. Terminal half life (t½)

    Terminal half life (t½) of KINE-101 following single and multiple doses.

    Time frame: From Day 1 (pre-dose) through Day 7 post-dose

Other outcomes

  1. Change from baseline in serum biomarkers following KINE-101 administration

    The change from baseline in serum biomarkers following intravenous administration of KINE-101 including IgG, IgM, IL-2, IL-6, IL-10, IL-17, IFN-gamma, MCP-1, and TGF-beta.

    Time frame: From Day 1 to Day 35 (End of Study visit)

  2. Change from baseline in immunophenotyping markers following KINE-101 administration

    The change from baseline in immunophenotyping markers following intravenous administration of KINE-101 including CD4, CD25, FoxP3, CD39, CD69, LAG-3, CTLA-4, TNFR2, TIGIT, CCR5, and CXCR3.

    Time frame: From Day 1 to Day 35 (End of Study visit)

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, North Chungcheong 28644, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Aug 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 7, 2026
StartActual
May 26, 2025
Primary completionActual
Aug 25, 2025
CompletionActual
Aug 25, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07324642
Lead sponsor
Kine Sciences Co., Ltd.
Collaborators
Chungbuk National University Hospital
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
May 26, 2025
Primary completion
Aug 25, 2025
Completion
Aug 25, 2025
Last update
Jan 7, 2026

Study contacts

Hanna Park
study director · Kine Sciences Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KINE-101

Start the discussion